Bulletin
Investor Alert

New York Markets Open in:

Horizon Therapeutics PLC

NAS: HZNP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 24, 2022, 6:12 p.m.

/zigman2/quotes/206690250/composite

$

88.93

Change

+0.90 +1.02%

Volume

Volume 193,421

Quotes are delayed by 20 min

/zigman2/quotes/206690250/composite

Previous close

$ 87.38

$ 88.03

Change

+0.65 +0.74%

Day low

Day high

$87.12

$89.45

Open

52 week low

52 week high

$82.51

$120.54

Open

Michael G. Grey

Michael G. Grey is an entrepreneur and businessperson who founded Mirum Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc. and Lumena Pharmaceuticals, Inc. and who has been at the helm of 17 different companies. Presently, Mr. Grey holds the position of Executive Chairman at Reneo Pharmaceuticals, Inc., Executive Chairman for Spruce Biosciences, Inc., Chairman of Mirum Pharmaceuticals, Inc., Executive Chairman of Plexium, Inc., Chairman for Sorriso Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. He is also on the board of Biothera, Inc., Horizon Therapeutics Plc and San Diego Venture Group.

In the past Michael G. Grey was Director at Curzion Pharmaceuticals, Inc., President & Chief Operating Officer for Ansan, Inc., Non-Executive Chairman at IDM Pharma, Inc., Executive Chairman for Amplyx Pharmaceuticals, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President & Chief Executive Officer of SGX Pharmaceuticals, Inc., President & Chief Operating Officer for Ansan Pharmaceuticals, Inc., President & Chief Executive Officer at Auspex Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., Vice President-Corporate Development at Glaxo, Inc. and Vice President-Corporate Development for Glaxo Holdings Plc.

He received an undergraduate degree from The University of Nottingham.

Transactions

Date Shares Transaction Value
04/29/2022 1,139   Derivative/Non-derivative trans. at $98.56 per share. 112,260
04/29/2022 4,223   Derivative/Non-derivative trans. at $0 per share. 0
07/22/2021 4,000   Disposition at $100.05 per share. 400,200
07/22/2021 1,000   Disposition at $100 per share. 100,000
07/22/2021 5,000   Derivative/Non-derivative trans. at $2.37 per share. 11,850
04/30/2021 2,993   Derivative/Non-derivative trans. at $94.62 per share. 283,198
04/30/2021 11,098   Derivative/Non-derivative trans. at $0 per share. 0
04/12/2021 15,000   Disposition at $90.28 per share. 1,354,200
04/12/2021 15,000   Derivative/Non-derivative trans. at $2.37 per share. 35,550
08/05/2020 1,755   Disposition at $73.35 per share. 128,730
08/05/2020 1,755   Derivative/Non-derivative trans. at $3.95 per share. 6,932
07/22/2020 1,755   Disposition at $60 per share. 105,300
07/22/2020 1,755   Derivative/Non-derivative trans. at $3.95 per share. 6,932
06/25/2020 1,755   Disposition at $55 per share. 96,525
06/25/2020 1,755   Derivative/Non-derivative trans. at $3.95 per share. 6,932
05/22/2020 10,530   Disposition at $48.77 per share. 513,549
05/22/2020 10,530   Derivative/Non-derivative trans. at $7.84 per share. 82,555
05/02/2020 15,390   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2019 4,132   Derivative/Non-derivative trans. at $26.54 per share. 109,664
05/03/2019 15,320   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2018 3,790   Derivative/Non-derivative trans. at $13.87 per share. 52,568
05/03/2018 14,054   Derivative/Non-derivative trans. at $0 per share. 0

Officers and Executives

Mr. Timothy P. Walbert
Chairman, President & Chief Executive Officer
Mr. Aaron L. Cox
Chief Financial Officer & Executive Vice President
Dr. Karin Rosen
Chief Scientific Officer
Dr. Elizabeth H. Z. Thompson
Executive Vice President-Research & Development
Dr. Jeffrey W. Sherman
Chief Medical Officer & Executive Vice President
Mr. Michael A. DesJardin
Executive VP-Technical Operations & Quality
Dr. Jeffrey D. Kent
Executive VP-Medical Affairs & Outcomes Research
Mr. Andy Pasternak
Chief Strategy Officer & Executive Vice President
Ms. Holly Copeland
Senior Director-Corporate Social Responsibility
Ms. Marilyn Vetter
Group Vice President-Market Access
Mr. Vikram Karnani
President-International & Executive Vice President
Mr. Miles W. McHugh
Chief Accounting Officer & Senior Vice President
Ms. Tina Ventura
Chief Investor Relations Officer & Senior VP
Ms. Jane Gonnerman
Chief of Staff & Group Vice President-Development
Ms. Irina P. Konstantinovsky
EVP, Chief Human Resources & Diversity Officer
Mr. David Caraher
Secretary
Mr. Sean M. Clayton
Executive Vice President & General Counsel
Dr. Susan Mahony
Independent Director
Mr. Michael G. Grey
Lead Independent Director
Dr. Jeff Himawan
Independent Director
Mr. William Francis Daniel
Independent Director
Ms. Pascale Witz
Independent Director
Dr. James Samuel Shannon
Independent Director
Mr. H. Thomas Watkins
Independent Director
Mr. Gino Santini
Independent Director
Link to MarketWatch's Slice.